Barrett's esophagus (BE) is defined by the replacement of the normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium.
Barrett's esophagus (BE) is defined by the replacement of the normal squamous epithelium of the distal esophagus with metaplastic intestinal-type columnar epithelium. [1] [2] [3] BE is an adverse event of chronic GERD and the only identifiable premalignant condition for esophageal adenocarcinoma (EAC), a cancer that continues to increase in incidence. In 2014 there were approximately 18,170 incident cases of esophageal cancer in the United States, nearly 60% of which were EAC. [4] [5] [6] Although uncommon, EAC is a highly lethal cancer associated with a poor 5-year survival rate of 15% to 20% and an overall median survival of <1 year in cases with advanced disease. [5] [6] [7] It is estimated that BE is present in 1% to 2% of the general adult population. 8, 9 The stepwise and hypothesized progression of BE to invasive EAC is believed to occur through the histopathologic stages of intestinal metaplasia to low-grade dysplasia (LGD) to high-grade dysplasia (HGD) to intramucosal EAC and finally to invasive EAC. 3, [10] [11] [12] [13] Endoscopic eradication therapy (EET) has significantly changed the management of patients with BE-related neoplasia and allows a minimally invasive treatment approach that avoids the morbidity and mortality associated with esophagectomy. Contemporary EET, supported by published literature, entails endoscopic mucosal resection (EMR) of visible lesions within the Barrett's segment and ablative techniques that include radiofrequency ablation (RFA) and cryotherapy. Several studies, including randomized controlled trials (RCTs), large observational studies, and population-based studies, have demonstrated the efficacy, effectiveness, and safety of EET to achieve complete eradication of intestinal metaplasia (CE-IM) and neoplasia while maintaining disease remission. [14] [15] [16] [17] [18] [19] [20] [21] [22] In addition, population-based studies report comparable outcomes between esophagectomy and EET in the management of BE-related HGD and mucosal EAC. 23 Available data suggest that EET is being performed not only at academic and tertiary care centers but also among community practices. 14, 18 
AIMS/SCOPE
The aim of this document is to offer evidence-based recommendations and clinical guidelines addressing key issues related to EET in the management of BE-related neoplasia. This document addresses the following clinical questions: 1. What is the role of confirmation of diagnosis by an expert GI pathologist or by a panel of pathologists in BE patients with dysplasia or intramucosal EAC referred for EET? 2. Comparing EET with surveillance, what is the optimal management strategy in BE patients with dysplasia (HGD and LGD) and intramucosal EAC? 3. Comparing EET with esophagectomy, what is the optimal management strategy in BE patients with HGD and intramucosal EAC? 4. What is the role of EMR in BE patients with a visible lesion detected during screening or surveillance? 5. What is the role of ablation of the remaining BE segment after EMR of all visible lesions in BE patients referred for EET? 6. Comparing EMR of visible lesions followed by ablation of remaining BE segment with EMR of entire BE segment, what is the optimal EET approach in BE patients with dysplasia or intramucosal EAC referred for EET? 7. After achieving CE-IM, what is the role of surveillance endoscopy? This document was approved by the American Society for Gastrointestinal Endoscopy (ASGE) Governing Board and represents the official recommendations of the ASGE.
conjunction with a Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodologist. It includes a systematic review of available literature along with guidelines for EET in the management of BErelated dysplasia and intramucosal EAC patients, developed using the GRADE framework. 24 After evidence synthesis, recommendations were drafted by the full panel during a face-to-face meeting on March 23, 2017 and approved by the Standards of Practice committee members and the ASGE Governing Board.
Panel composition and conflict of interest management
The panel consisted of 2 content experts with expertise in systematic reviews and meta-analysis (S.W., B.Q.), a GRADE methodologist (S.S.), oncologic surgeon, committee chair (J.D.), patient representative, and other committee members. All panel members were required to disclose potential financial and intellectual conflicts of interest, which were addressed according to ASGE policies (https://www.asge.org/forms/conflict-of-interest-disclosure and https://www.asge.org/docs/default-source/about-asge/ mission-and-governance/asge-conflict-of-interest-and-discl osure-policy.pdf).
Formulation of clinical questions
A total of 7 clinical questions were developed and then approved by the ASGE Governing Board (Table 1) . For each PICO question we identified the population (P), intervention (I), comparator (C), and outcomes of interest (O) . For all clinical questions potentially relevant patient-important outcomes were identified a priori and rated from not important to critical through a consensus process. Relevant clinical outcomes included progression to cancer, cancer-specific and all-cause mortality, adverse events, and recurrence rates. EET in this document refers to EMR and RFA (based on the vast body of literature) unless explicitly stated otherwise.
Literature search and study selection criteria
For each of the PICO questions a literature search for existing systematic reviews and meta-analyses was performed. If none was identified, a full systematic review and meta-analysis (when possible) was conducted using the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-analyses criteria. 25 Details of the search strategy are reported in Supplementary Text 1 (available online at www.giejournal.org). A medical librarian (B.H.) performed a comprehensive literature search of Ovid Medline (Ovid MEDLINE in-process and other non-indexed citations, Ovid MEDLINE) Daily and Ovid MEDLINE 1946 to present), Embase (via Embase. com), and the Cochrane Database of Systematic Reviews/ Cochrane Register of controlled trials (via Wiley Online Library). All searches ended on March 11, 2016 . Inclusion and exclusion criteria were developed for each PICO question (Supplementary Text 2, available online at www. giejournal.org).
Citations were imported into EndNote (Thompson Reuters, Philadelphia, Pa), and duplicates were removed. The EndNote library was then uploaded into Covidence (www.covidence.org). Two reviewers were assigned to each search for each PICO question. Studies were first screened by title and abstract and then by full text, and all conflicts were resolved by consensus. If existing systematic reviews and meta-analyses were available, inclusion and exclusion criteria were reviewed, and methodological quality of the study was assessed using the Measurement Tool to Assess Systematic Reviews (AMSTAR) tool (https://amstar.ca/Amstar_Checklist.php). 26 Only systematic reviews and meta-analysis meeting the quality thresholds were used for data synthesis. For this guideline an arbitrary threshold (meeting 8 or more of the 11 criteria) was used. When applicable, available systematic reviews and meta-analyses were updated based on literature review as described above.
Data extraction and statistical analysis
If data extraction was needed for a meta-analysis, data were extracted by 2 independent reviewers using Microsoft Excel (Microsoft Corporation, Redmond, Wash). The primary estimate of effect was based on the outcomes of interest in the PICO question and included relative risk (RR), odds ratio (OR), or proportions (change in diagnosis, cumulative rate of disease progression, among others). For outcomes with limited or no available direct comparisons, indirect comparisons were used to estimate the magnitude and direction of effect. Heterogeneity was assessed using the I 2 and Q statistic. Significant heterogeneity was defined at I 2 > 50% and significant P value (<.05) on the Q statistic. Random-effects models were used if significant heterogeneity was detected. Otherwise, fixed-effects models were used. Studies were weighted based on their size. A priori sources of heterogeneity for each outcome were hypothesized and addressed in sensitivity analyses when applicable. Publication bias was assessed using funnel plots and the classic-fail-safe. Statistical analyses were performed using Comprehensive Meta Analysis V 3 (Biostat Inc, Englewood, NJ).
Certainty in evidence (quality of evidence)
The certainty in the body of evidence (also known as quality of the evidence or confidence in the estimated effects) was assessed for each effect estimate of the outcomes of interest, following the GRADE approach based on the following domains: risk of bias, precision, consistency and magnitude of the estimates of effects, directness of the evidence, risk of publication bias, presence of doseeffect relationship, and an assessment of the effect of residual, opposing confounding. The certainty was categorized into 4 levels ranging from very low to high (Table 2) . With this approach direct evidence from RCTs starts at high quality and is then rated down based on assessment of the above variables. On the other hand, evidence from observational studies starts at low quality and then is potentially downgraded based on the above variables or upgraded in case of the dose-response relationship and large magnitude of effect. For each PICO an evidence profile or summary of findings table was created using the GDTpro application (http://gdt. guidelinedevelopment.org/app).
Considerations in the development of recommendations
During an in-person meeting, the panel developed recommendations based on the following: the certainty in the evidence, the balance of benefits and harms of the compared management options, the assumptions about the values and preferences associated with the decision along with available data on resource utilization, and cost-effectiveness. The final wording of the recommendations (including direction and strength), remarks, and qualifications were decided by consensus and were approved by all members of the panel. The recommendations are labeled as either "strong" or "conditional" according to the GRADE approach. The words "the guideline panel recommends" are used for strong recommendations and "suggests" for conditional recommendations. Table 3 provides the suggested interpretation of strong and conditional recommendations by patients, clinicians, and healthcare policymakers. Patient values and preferences. Limited data address patient preferences with regards to management of BE with and without dysplasia. Three studies shed light on this important subject. [27] [28] [29] In a prospective study Yachimski et al 27 showed that patients with nondysplastic BE (NDBE) preferred endoscopic ablation over chemoprevention (aspirin) to prevent progression of BE to EAC. Rosmolen and colleagues 29 assessed the influence of EET and surgery on quality of life and fear of cancer recurrence. In this study that included 66 patients treated with EET and 29 patients undergoing esophagectomy, patients in the surgery group reported more eating problems (OR, 18.3; 95% CI, 4.1-81.5) and reflux symptoms (OR, 3.4; 95% CI, 1-10.5), whereas endoscopy patients reported greater fear of recurrence. These results highlight the need for proper patient education with a specific focus on cancer recurrence in patients undergoing EET. There are no recent studies of patient preferences for management of BE-related neoplasia using contemporary endoscopic therapies (EMR, RFA, cryotherapy), surgical esophagectomy, and surveillance.
Cost-effectiveness. Several studies have demonstrated the cost-effectiveness of contemporary EET in the management of BE-related neoplasia. Hur et al 30 analyzed the cost-effectiveness of RFA for management of BE using a decision analytic Markov model, and separate analyses of hypothetical cohorts of BE with dysplasia (HGD and LGD) and NDBE were conducted. In HGD patients treatment strategies compared were (1) endoscopic surveillance with esophagectomy when cancer was detected and (2) initial RFA followed by endoscopic surveillance. Treatment options for confirmed and stable LGD patients included (1) endoscopic surveillance with surgery when cancer Further research is very unlikely to change our confidence in the estimate of the effect.
Moderate
We are moderately confident in the estimate of the effect; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Further research is likely to have an impact on our confidence in the estimate of the effect and may change the estimate.
Low
Our confidence in the estimate of the effect is limited; the true effect may be substantially different from the estimate of the effect.
Further research is very likely to have an impact on our confidence in the estimate of the effect and is likely to change the estimate.
Very low
We have very little confidence in the estimate of the effect; the true effect is likely to be substantially different from the estimate of the effect.
Any estimate of the effect is very uncertain.
GRADE, Grading of Recommendations Assessment, Development and Evaluation. Recognize that different choices will be appropriate for individual patients and that you must help each patient arrive at a management decision consistent with his or her values and preferences. Decision aids may be useful in helping individuals to make decisions consistent with their values and preferences.
Policymakers
The recommendation can be adopted as policy in most situations. Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator.
was detected, (2) endoscopic surveillance with RFA when diagnosed with HGD, and (3) initial RFA at LGD stage followed by endoscopic surveillance. In patients with HGD this analysis showed that RFA was more effective and less costly than surveillance followed by esophagectomy at the detection of EAC (.704 more quality-adjusted life years and costing $25,609). Initial RFA was also cost-effective for confirmed and stable LGD and not cost-effective in NDBE patients. Data from a recent RCT showed that ablation with RFA for patients with confirmed LGD is more effective and more expensive than surveillance in reducing the risk of progression to the endpoint of HGD/EAC. 31 Similarly, a decision analysis that compared cost-effectiveness of esophagectomy and EET in the treatment of early EAC showed that EET was more effective and less expensive than esophagectomy. 32 EET was also a cost-effective alternative in patients with submucosal cancer, especially in patients with high operative risk.
RESULTS
The recommendations, quality of evidence, and strength of recommendations are summarized in Table 4 .
The panel members recommend that before embarking on EET, patients have a clear understanding of the risks, benefits, and alternatives to EET.
The panel members agreed that before EET, clinicians should obtain informed consent that includes discussions of the natural history of BE including progression rates to EAC, appropriate surveillance and treatment options, risks and benefits of each approach, and the frequency of EET sessions and duration of follow-up. 14, 15 Patient preferences and assessment of patient comorbidities and life expectancy should be considered in the management algorithm of these patients.
Question 1: What is the role of confirmation of diagnosis by an expert GI pathologist or by a panel of pathologists in BE patients with dysplasia or intramucosal EAC referred for EET?
Recommendation: In BE patients with HGD and LGD being considered for EET, we suggest confirmation of diagnosis by at least 1 expert GI pathologist or a panel of pathologists compared with review by a single pathologist (conditional recommendation, low quality of evidence).
Summary of the Evidence: The patient important outcomes for this clinical question were the differences in progression rates to cancer among patients with confirmed dysplasia (critical outcome) and proportion of patients with a change in diagnosis in grade of dysplasia based on an expert pathology review or review by a panel of pathologists (important outcome). No RCTs addressed these outcomes, and hence indirect comparisons from observational studies were used to inform this recommendation. The evidence profile for this clinical question is summarized in Table 5 .
Progression rates to EAC or a composite endpoint of HGD/EAC based on expert pathology review have been Fig. 1 , available online at www. giejournal.org). These results demonstrate that LGD, as confirmed by expert pathologist/panel of pathologists, was associated with a higher rate of disease progression to HGD/EAC.
A systematic review and meta-analysis was conducted to address the question of change in diagnosis (grade/presence of dysplasia) based on expert pathology review. Of the 682 screened studies, 43 were reviewed in full text format and 8 were included in the final analysis and included a total of 2354 patients. Using a random-effects model, expert pathology review resulted in a change in the pathologic diagnosis (upgrading or downgrading) in 55% (95% CI, 31%-77%) of all patients. In most studies this change was associated with downgrading to a lower pathologic diagnosis (36% [95% CI, 18%-59%]) (Fig. 1 Certainty in the Evidence: For the critical outcome of disease progression, the quality of evidence was low based on the use of observational studies. There was no serious risk of bias, inconsistency, indirectness, imprecision, or publication bias. For change in dysplasia diagnosis (important outcome), the quality of evidence was rated down for inconsistency given the high I 2 , suggesting significant heterogeneity. Hence, the quality of evidence for this outcome was very low. The overall body of evidence across all outcomes was deemed low quality.
Considerations: One potential downside is increased cost associated with expert pathology review because of limited local expertise. Given the important potential impact on patient management and that coverage is usually provided by medical insurance providers, the costs associated with this intervention did not impact the recommendation provided.
Discussion: Despite recent advances in genetic and molecular markers, the degree of dysplasia is still the best biomarker to predict progression to EAC and guide further management. 3 The revised Vienna classification for GI mucosal neoplasia and the World Health Organization classification of GI tumors are the grading systems used to categorize the grade of dysplasia in BE patients. 35, 36 Significant interobserver and intraobserver variability has been well described among community and expert pathologists, especially regarding the diagnosis of LGD. 11, [37] [38] [39] [40] Results from a U.S. multicenter cohort study showed that the interobserver agreement among 2 expert central GI pathologists for the diagnosis of LGD was slight (k value Z .14). 11 A recent study that included 7 expert pathologists from the United States and Europe showed that the k value for NDBE was .22 (95% CI, .11-.29), LGD .11 (95% CI, .004-.15), and HGD .43 (95% CI, .36-.46), reaffirming the high interobserver variability even among expert pathologists.
As described above, there is evidence across multiple studies and various outcomes that review by an expert pathologist or panel of pathologists affects outcomes in patients with BE, especially in BE patients with LGD. The exact definition of an expert pathologist is debatable. A recent expert review from the Clinical Practice Updates Committee of the American Gastroenterological Association defined an expert pathologist as one with a special interest in BE-related neoplasia and recognized as an expert in this field by his or her peers. 3 It is beyond the scope of this clinical guideline to define the detailed criteria that should be used in practice by pathologists and how they should arrive at a consensus diagnosis.
Finally, this recommendation is consistent with other published guidelines and supports the idea of confirmation of dysplasia by at least 1 expert GI pathologist or a panel of pathologists.
2 This is what practitioners should be doing in clinical practice. Given the low quality of evidence Change in dysplasia diagnosis when >1 expert GI pathologist confirmed the diagnosis (pooled event rate across 8 studies) was 55% (range, 31%-77%), with most cases being downgraded.
supporting this recommendation, there is an opportunity for more and better evidence to inform this recommendation. This recommendation was also recently included as 1 of the ASGE and American College of Gastroenterology endorsed quality indicators for EET in BE.
14,41
Question 2a: Comparing EET with surveillance, what is the optimal management strategy in BE patients with LGD?
Recommendation: In BE patients with LGD, we suggest EET compared with surveillance (conditional recommendation, moderate quality evidence); however, patients who place a high value on avoiding adverse events related to EET may choose surveillance as the preferred option.
Summary of the Evidence: The patient-important outcomes of interest for this clinical question were differences in progression rates to cancer, cancer-specific mortality, all-cause mortality, and adverse events. The evidence for these outcomes was informed by 2 recent systematic reviews (see Table 6 ). 22, 33 Qumseya et al 33 conducted a systematic review and meta-analysis comparing the risk of progression to HGD/EAC among BE patients with LGD treated with RFA compared with surveillance endoscopy using data from 22 studies of over 2500 patients. Three head-to-head studies (2 RCTs 16, 17 and 1 retrospective 42 ) assessed the primary outcome of the RR of disease progression among patients treated with RFA compared with surveillance. For the purposes of this guideline the RR was calculated using data from the 2 RCTs only. When fixed-effects models are used, the RR of disease progression in BE patients with LGD treated with RFA compared with surveillance was .16 (95% CI, .04-.57; P Z .001) (Fig. 2) . Considering the entire body of evidence by incorporating observational studies, a total of 22 studies including the above RCTs (2746 patients) reported similar results (RR Z .14 of disease progression in patients treated with RFA compared with surveillance) (Fig. 3) . The cumulative rate of disease progression (follow-up up to 84 months) among patients who underwent surveillance was 12.6% (95% CI, 9.8%-15.9%) and for patients who received RFA was significantly lower at 1.7% (95% CI, 1.1%-2.6%). The magnitude and direction of this estimate was very similar to the results of the 2 RCTs. This analysis also demonstrated that the incidence rate of progression among patients undergoing surveillance was significantly higher than those treated with RFA (.022 [95% CI, .015-.03] vs .005 [95% CI, .002-.007]). The outcome of serious adverse events for patients undergoing RFA was also addressed using a recent systematic review and metaanalysis. 22 This analysis included 37 studies with 9200 patients and reported a pooled rate of serious adverse events of 8.8% (95% CI, 6.5%-11.9%) related to RFA with Fig. 2 , available online at www. giejournal.org). None of the published studies compared the outcomes of all-cause and cancer-related mortality. A recent study reported the EAC-specific and all-cause mortality in BE patients undergoing RFA (n Z 4982). 18 Among LGD patients (n Z 1020), the adjusted all-cause mortality rate was 6.8 per 1000 person-years (95% CI, 3.4-10.1), and none of the patients died from EAC. Certainty in the Evidence: For the outcome of disease progression, we evaluated the RCT studies separately from the observational studies. The 2 RCTs started as highquality evidence, but we rated down for imprecision. For the observational studies the overall quality of evidence was very low after we rated down for significant heterogeneity, and even with very low quality of evidence, the magnitude and direction of the effect estimate strongly supports the evidence from the 2 RCTs. For the outcome of adverse events, the quality of evidence was low. Considerations: In absolute terms the risk of progression to HGD/EAC in BE patients with confirmed LGD (diagnosis confirmed by an expert/panel pathologists) was estimated as 25 per 100 patients in the surveillance arm over a follow-up duration of up to 84 months. Treating 100 patients with EET would lead to 21 fewer patients (95% CI, 11 fewer to 24 fewer) with HGD/EAC and 9 adverse events, mostly strictures that were believed to be treatable. The previously described data on costeffectiveness also factored into this risk-to-benefit assessment. 30, 31 There are limited to no data addressing the issue of patient preferences and burden and inconvenience associated with either of these treatment approaches.
Discussion: This recommendation places a high value on the potential benefit of EET on patient-important outcomes and a lower value on potential adverse effects and patient burden or inconvenience (based on feedback from the patient representative). The management of BE patients with LGD continues to generate a great deal of controversy. 3 Although the primary outcome of the evidence was RR of disease progression among BE patients with LGD treated with RFA compared with surveillance, similar beneficial effects were noted while assessing incidence rate of disease progression, progression to HGD only, and progression to EAC only. The panel recognized there were no direct data on the following patient-important outcomes: cancer-specific mortality and all-cause mortality. Additionally, panel members also discussed factors that supported a strategy of continued surveillance such as (1) unclear generalizability of above results as the safety and effectiveness have predominantly been shown at expert centers, (2) lack of clear diagnostic pathologic criteria for LGD and significant interobserver variability among pathologists regarding the diagnosis of LGD (though confirmation by an expert or panel of pathologists may mitigate this variability), (3) phenomenon of regression of LGD (inability to demonstrate LGD on subsequent endoscopy), and (4) surveillance of LGD, at least at expert centers, detects progressors at a stage amenable to EET and rarely required esophagectomy. 3 Evidence-based recommendations regarding surveillance intervals are not available. A recent expert review on LGD suggests that in patients with LGD undergoing surveillance rather than EET, surveillance should be performed every 6 months times 2 and then annually unless there is reversion to NDBE and that biopsy sampling should be obtained in 4 quadrants every 1 to 2 cm and of any visible lesions. 3 Improved risk stratification with reliable predictors of progression has the potential to better define individuals at the highest risk of progression to HGD/EAC and thus most likely to benefit from EET. Given the importance of risk stratification, the panel members reviewed the results of studies assessing predictors of progression in BE patients with LGD. 3 BE patients with confirmed LGD (defined by confirmation of diagnosis by an expert pathologist or a panel of pathologists) are at a higher risk of progression to HGD/ EAC. In addition, recent studies have identified persistent LGD (defined by the presence of LGD on 2 consecutive endoscopies) as a risk factor for progression in LGD patients. 3, 34, 43, 44 With the exception of confirmed and persistent LGD, no other variable appears to be reproducibly associated with progression in LGD patients. In addition, although several biomarkers have been studied to improve risk stratification, none is ready for application in clinical practice. Effect estimates were explored based on stratifying patients into a high-or low-risk group based on confirmed and persistent LGD (Table 6 ). However, given the limited data, the panel decided against providing recommendations based on the risk group but emphasized the importance of confirmation of LGD (see Question 1) and highlighting the need for a shared decision-making approach with specific discussion with the patient about his or her values and preferences for treatment.
Question 2b: Comparing EET with surveillance, what is the optimal management strategy in BE patients with HGD?
Recommendation: In BE patients with HGD, we recommend EET compared with surveillance (strong recommendation, moderate quality evidence).
Summary of the Evidence: The primary outcomes of interest for this clinical question were differences in progression rates to cancer, cancer-specific and all-cause mortality, and adverse events (Table 7) . A systematic review and meta-analysis was conducted to address this clinical question. A total of 1909 citations were identified, and 20 studies (including 2 RCTs) were included in the final analysis. Progression to EAC was assessed in 2 RCTs; Overholt et al 45 compared photodynamic therapy (PDT) versus surveillance (study follow-up, up to 43 months), and Shaheen et al 16 compared RFA versus surveillance in BE patients with HGD (study follow-up, up to 1 year). When fixed-effects models were used, the RR of disease progression in comparing EET with surveillance was .42 (95% CI, .24-.73; P Z .0002) (Fig. 4) . These results were supported by the body of indirect evidence that compared disease progression rates in patients treated with EET with those undergoing surveillance (2478 patients, number of progressors to EAC Z 418). The cumulative risk of disease progression in the surveillance group was 34% (95% CI, 25.5%-43.8%) and in the EET group 7.4% (95% CI, 4.5%-11.7%) with a calculated RR of .22 (Fig. 5 ). Significant heterogeneity was noted, and funnel plots and the classic fail safe showed low risk of publication bias.
The outcome of adverse events for all patients undergoing RFA with or without EMR was informed by the recent systematic review and meta-analysis by Qumseya et al, 22 which included 37 studies (9200 patients) and reported a pooled rate of adverse events of 8.8% (95% CI, 6.5%-11.9%) related to RFA with or without EMR. Esophageal stricture formation was the most common adverse event (5.6% [95% CI, 4.2%-7.4%]). Bleeding (1% [95% CI, .8%-1.3%]) and perforation (.6% [95% CI, .4%-.9%]) were less common adverse events (Supplementary Fig. 2) . A subanalysis addressing adverse events only in BE patients with HGD/intramucosal EAC showed a pooled rate of adverse events (10.6% [95% CI, 5.7%-19.1%]) that was similar to the overall adverse event rate (Fig. 6) . Limited data address the outcomes of all-cause and cancer-related mortality. A recent study reported the EAC-specific and all-cause mortality in BE patients undergoing RFA (n Z 4982). 18 Among HGD patients (n Z 990), the adjusted all-cause mortality rate was 24.8 per 1000 person-years (95% CI, 12.1-37.4) and EAC-related mortality rate 2.0 per 1000 person-years (95% CI, .8-4.5).
Certainty in the Evidence: For the outcome of disease progression to EAC addressed by the 2 RCTs, the quality of evidence was rated down for imprecision given the wide CIs. Although the RCT by Overholt et al 46 compared PDT with surveillance, we did not rate down for indirectness. For the studies that provided indirect comparison in progression rates between patients treated with EET and those undergoing surveillance, the quality of evidence was low given that most were observational studies. The quality of evidence was rated down further for inconsistency. For the outcome of adverse events, the quality of evidence was low.
Considerations: For this recommendation the panel placed a high value on the potential benefit of EET on patient-important outcomes, specifically risk of progression to EAC and a lower value on potential adverse effects. Costeffectiveness analyses, described earlier, clearly demonstrate that among BE patients with HGD, RFA was more effective and less costly than endoscopic surveillance.
Discussion: Available evidence supports a strong recommendation for EET in the management of BE patients with HGD/intramucosal EAC compared with surveillance.
Question 3: Comparing EET with esophagectomy, what is the optimal management strategy in BE patients with HGD and intramucosal EAC?
Recommendation: In BE patients with HGD/intramucosal EAC, we recommend against surgery compared with EET (strong recommendation, very low-quality evidence).
Summary of the Evidence: The patient-important outcomes for this clinical question were differences in complete eradication rates of dysplasia/intramucosal EAC, recurrence rates, overall survival, EAC-related mortality, and adverse events. An existing systematic review and meta-analysis by Wu et al 46 was updated (794 studies were screened and 13 full-text articles were reviewed) to inform this question (Table 8) . 23, 47 Two studies were added to the final analysis for the 5-year survival data. There was no difference between the 2 treatment modalities for the endpoint of complete eradication of HGD/intramucosal EAC (RR, .96; 95% CI, .91-1.01). Recurrence rate of neoplasia was higher in the EET group (RR, 9.5; 95% CI, 3.26-27.75). There was no difference between the 2 groups with regard to overall survival (1-, 3-, and 5-year survival) and EAC-related mortality. For the important outcome of 5-year survival, there was no difference between the 2 groups, with an RR of .88 (95% CI, .74-1.04; Fig. 7 ). Patients undergoing EET had significantly lower rates of adverse events compared with esophagectomy (RR, .38; 95% CI, .20-.73).
Certainty in the Evidence: The evidence supporting this recommendation was provided by observational studies (retrospective single-institutional or populationbased studies using the Surveillance, Epidemiology and End Results database) starting out as low quality of evidence. However, the quality of evidence was rated up to moderate for the endpoints of complete eradication, overall survival at 1 and 3 years, and major adverse events given the selection bias in the included studies where patients with multiple comorbid illnesses were more likely to undergo EET compared with esophagectomy and that accounting for all plausible confounding would actually reduce the demonstrated effect. The quality of evidence was very low for recurrence rates after EET and esophagectomy (rated down for imprecision because only 1 recurrence was seen in the surgery group) and overall survival at 5 years (rated down for inconsistency). Similarly, the quality of evidence for EAC-related mortality was rated down to very low given the sparse events in both groups.
Considerations: This recommendation places a high value on the potential adverse effects associated with esophagectomy as compared with EET. Adverse events related to esophagectomy include bleeding, anastomotic leakage, stenosis, prolonged hospitalization, and death. This analysis demonstrated a lower risk of major adverse events associated with EET (16 fewer per 100 adverse events compared with the esophagectomy). The adverse events related to EET were mostly bleeding, perforation, and stricture formation, as discussed above. The absolute risk of recurrence of neoplasia was minimally higher in the EET group with 2 more recurrences of neoplasia per 100 patients compared with the esophagectomy group. Limited data address the issue of patient values, preferences, and burden associated with either of these treatment approaches. As highlighted earlier, a study assessing the influence of EET and esophagectomy on quality of life showed that patients undergoing EET reported a greater fear of recurrence. 29 Discussion: Given the high tumor-free survival rates, esophagectomy was the standard treatment for BE patients with HGD and intramucosal EAC, and all other therapies were compared with this modality. 23 Esophagectomy, especially in patients in whom the cancer had not yet penetrated the muscularis mucosa, is associated with a high 5-year survival rate. 48 However, this treatment approach is associated with an operative mortality of 2% and a high morbidity rate seen even at high-volume centers. 48, 49 The basic premise of EET is that BE patients with HGD and intramucosal EAC have a very low risk of lymph node metastasis (0% in patients with HGD and up to 2% in patients with intramucosal EAC). 50 The effectiveness and safety profile of EET in BE-related neoplasia has been well established. [14] [15] [16] [17] [18] [19] [20] [21] [22] However, comparative studies between esophagectomy and EET are limited. Unfortunately, no RCT(s) was available to provide conclusive evidence regarding superiority of 1 of these 2 treatment modalities, and no such trial is expected in the foreseeable future. The effectiveness and safety of EET and adverse events associated with esophagectomy were important considerations for this recommendation. Another important determinant was the higher recurrence rate of neoplasia associated with EET compared with esophagectomy. Recurrence of intestinal metaplasia and neoplasia after EET was addressed in 2 recent systematic reviews and meta-analyses. 51, 52 These studies demonstrated that >95% of all recurrences were successfully treated with EET, adding credence to use of EET for the management of BE-related neoplasia patients. The panel members also accounted for the multiple endoscopy sessions required to achieve the goal of EET: complete eradication of dysplasia and CE-IM. 14, 22, 41 Most patients achieve CE-IM within 3 ablative therapy sessions. 53, 54 Esophagectomy is considered as the treatment of choice for patients with submucosal cancer (T1b sm2-3 disease), poorly differentiated cancer, and cancer associated with lymphatic or vascular infiltration given the high risk of lymph node metastasis (at least 20%). 2, 23, 55 Long-term survival data in patients undergoing EET using contemporary treatment modalities and identification of stage T1b EAC patients who may be able to undergo EET and achieve comparable outcomes with esophagectomy should be addressed in future studies. Studies identifying patient and provider-specific determinants of optimal outcomes, 14, 41 and studies on patient preferences and quality of life should be a research priority.
Question 4:
What is the role of EMR in BE patients with a visible lesion detected during screening or surveillance?
Recommendation: In BE patients referred for EET, we recommend endoscopic resection of all visible lesions compared with no endoscopic resection of visible lesions (strong recommendation, moderate quality evidence).
Summary of the Evidence: The patient-important outcomes for this clinical question were the difference in progression rates to cancer among BE patients who underwent EMR of visible lesions (typically described as areas with nodularity, ulceration, plaques, areas of depression, or mucosal discoloration) compared with those who did not undergo EMR of visible lesions (important outcome), proportion of patients with a change in diagnosis in grade of dysplasia and those with a change in management plan as a result of EMR (critical outcome), and adverse events related to EMR (critical outcome). There were no RCTs that addressed these outcomes; hence, indirect comparisons from observational studies were used to provide this recommendation. The evidence profile for this clinical question is summarized in Supplementary Table 1 (available online at www.giejournal.org).
A systematic review and meta-analysis was conducted to address the question of change in diagnosis based on EMR. Of the 1436 screened studies, 17 were reviewed in full-text format and 14 were included in the final analysis. These studies included a total of 1116 patients with a total number of 449 events. When a random-effects model was used, EMR resulted in a change in the pathologic diagnosis in 39% (95% CI, 34%-45%) of all patients. Most of this change was associated with upgrading of grade of dysplasia/ neoplasia (Fig. 8) . Review of published literature identified no studies comparing progression rates and adverse events between patients undergoing EMR of visible lesions with those not undergoing EMR for visible lesions.
The safety of EMR in BE patients has been established in multiple studies. 22, 56, 57 In a cohort study of 681 patients treated at a tertiary care center, a total of 1388 endoscopic procedures were performed, and 2513 EMRs were performed using the cap or multiband mucosectomy technique. 56 No perforations were noted, bleeding post-EMR was seen in 8 patients (1.2%: 7 treated endoscopically and 1 required surgery), and strictures were reported in 7 patients (1%). Another large cohort study that included 1096 consecutive patients with intramucosal EAC who underwent 2687 EMR procedures reported a major adverse event rate of 1.5% (15 patients: major bleeding 14, perforation 1, stricture 13), and all adverse events were managed endoscopically. 57 The outcome of adverse events for patients undergoing EET was also addressed using a recent systematic review and meta-analysis. 22 Although the pooled rate of all adverse events with EET (RFA with or without EMR) was 8.8% (95% CI, 6.5%-11.9%), in studies that compared RFA with versus without EMR, the adverse event rate was significantly higher for RFA with EMR (RR, 4.4; P Z .015).
Certainty in the Evidence: For the outcome of change in diagnosis in grade of dysplasia, the quality of evidence was rated up for large effect; the consensus threshold was 20% among the panel members. There was no risk of bias, inconsistency, indirectness, imprecision, or publication bias.
Considerations: This recommendation placed a high value on the role of EMR in leading to change in diagnosis and the potential to impact patient management and outcomes. The benefits of EMR include assessment of histologic depth of invasion to improve confidence of clinical decisions made for patients with BE-related dysplasia and intramucosal EAC with EET. 58 By altering the diagnosis, EMR has the potential to impact the management plan (although the impact of EMR on the management plan was not consistently reported across published studies). Under-diagnosis or over-diagnosis may have substantial deleterious consequences for the patient. For example, a patient without cancer may undergo unnecessary esophagectomy or patients with submucosal invasive EAC may incorrectly be treated with EET instead of surgery. Given the importance and magnitude of the effect on patient management and low risk of adverse events, the panel members supported a strong recommendation for this clinical question.
Discussion: EMR plays a critical role as a part of the armamentarium for Barrett's EET and has evolved into an important diagnostic/staging and therapeutic tool in the management of BE-related neoplasia patients. 3, 59 The value of EMR as a diagnostic/staging tool is enhanced by the provision of larger and deeper tissue specimens (resection extends to muscularis mucosa and submucosal level in most EMR specimens) compared with biopsy specimens, with limited distortion allowing for an accurate assessment of depth of neoplastic involvement and adequacy of resection. 3 As highlighted above, a change in diagnosis in nearly 40% of patients was noted in BE patients undergoing EMR for visible lesions. In addition to the change in diagnosis, provision of a larger specimen (with EMR) to pathology results in an improvement in interobserver agreement among pathologists compared with biopsy specimens as demonstrated in at least 2 studies. 38, 60 The recommendation of performing EMR of all visible lesions (no matter how subtle) is consistent with other recent guideline documents, quality indicator documents, and current clinical practice.
Question 5: What is the role of ablation of the remaining BE segment after EMR of all visible lesions in BE patients referred for EET?
Recommendation: In BE patients with visible lesions who undergo EMR, we suggest ablation of remaining Barrett's segment compared with no ablation (conditional recommendation, low quality evidence).
Summary of the Evidence: The critical outcomes for this question included differences in progression rate to cancer along with comparison of recurrence rates between the 2 groups. Important outcomes included differences in progression rate to a combined endpoint of HGD/EAC and adverse events. A systematic review was conducted for this clinical question (1799 studies identified from literature search, 17 reviewed in full text format and 2 studies met inclusion criteria). 19, 62 Supplementary Table 2 (available online at www. giejournal.org) is a summary of the evidence that informed this recommendation. Pech et al 19 compared rates of metachronous neoplasia in BE patients with HGD and intramucosal EAC treated with EMR alone with those treated with ablative therapies (PDT and argon plasma coagulation [APC]) after EMR. In patients receiving ablative therapies of the remaining BE segment, the metachronous neoplasia rate was significantly lower compared with patients receiving no ablation (16.5% vs 29.9%, P Z .0014). Similar results were noted in the assessment of late occurrence of metachronous neoplasia (!24 months after achieving complete remission from neoplasia), with lower 
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MODERATE GRADE, Grading of Recommendations Assessment, Development and Evaluation; EET, endoscopic eradication therapy; BE, Barrett's esophagus; HGD, high-grade dysplasia; EAC, esophageal adenocarcinoma; CI, confidence interval; RR, relative risk; LGD, low-grade dysplasia; RCT, randomized control trial; IMC, intramucosal cancer; RFA, radiofrequency ablation. *I 2 was 48%; however, we did not rate down for inconsistency. yWe rated down for imprecision because of very few events in the surgery arm (1 recurrence). zWe rated down for inconsistency because I 2 was 82%, indicating considerable heterogeneity among studies, with some studies showing a benefit and others demonstrating no benefit. xWe rated down for imprecision because of sparse events (1 in each arm).
rates in the ablation group compared with the no ablation group (18% vs 32%, P Z .0053). Lack of ablation of the remaining BE was a significant predictor of recurrence after EMR of BE-related neoplasia (RR, 2.5; 95% CI, 1.52-3.85; P Z .0003). Manner et al 62 showed similar results in a RCT that compared EMR plus APC of the residual BE segment versus EMR alone. This trial was stopped early for benefit and showed that the risk of recurrence was significantly higher in the EMR alone group compared with the EMR plus APC group (36.7% vs 3%) at a follow-up period of 24 months.
Additionally, a recent multicenter study of BE patients treated with RFA with and without EMR used a logistic regression to evaluate factors associated with mortality. 18 On multivariate analysis, after adjustment for race, gender, and time in the study, predictors of mortality included increasing age (OR, 1.1/year) and increasing histologic grade (OR: LGD, 1.3; HGD, 2.7; intramucosal EAC, 2.1; and invasive EAC, 12). Achieving CE-IM was protective with an OR for mortality of .4 (95% CI, .3-.6). This evidence indirectly supports the need to ablate the remaining BE segment. The outcome of adverse events for patients undergoing RFA with or without EMR was addressed using a recent systematic review and metaanalysis. 22 Certainty in the Evidence: Although the study by Pech et al 19 included noncontemporary ablative therapies such as PDT (contemporary therapies include RFA and cryotherapy), the panel members did not rate down for indirectness. The RCT by Manner et al 62 was rated down for risk of bias, because the study was stopped early, and imprecision, given the few events noted. The overall quality of evidence across studies was low.
Considerations: This recommendation placed a high value on the potential benefits and a low value on potential adverse events including burden and cost. The benefits include reduction in the risk of metachronous neoplasia and thus the potential to reduce the risk of progression to invasive EAC. Multiple endoscopies are required to achieve the CE-IM, creating a burden to patients related to the risks of adverse events, discomfort, and time required to complete treatment. On the other hand, the risk of metachronous neoplasia and progression to invasive EAC may contribute to patient anxiety. Limited data 
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Risk ratio and 95% CI Statistics for each study Figure 7 . Forest plot of studies comparing overall 5-year survival between Barrett's esophagus patients with high-grade dysplasia/intramucosal cancer treated with endoscopic eradication therapy and esophagectomy. CI, Confidence interval.
address the issue of patient values, preferences, and burden associated with either of these treatment approaches.
Discussion: Available data support the current paradigm and goal of EET, which is CE-IM defined as the absence of endoscopically visible BE and all surveillance biopsy specimens demonstrating no intestinal metaplasia. 22 Based on the overall low quality of evidence, the panel members provided a conditional recommendation for ablation of the remaining Barrett's segment after performing EMR of all visible lesions. This recommendation is consistent with those provided by recent guidelines and quality indicator documents. 2, 3, 14, 41, 61 Question 6: Comparing EMR of visible lesions followed by ablation of the remaining BE segment with EMR of the entire BE segment, what is the optimal EET approach in BE patients with dysplasia or intramucosal EAC referred for EET?
Recommendation: In BE patients with dysplasia and mucosal EAC referred for EET, we recommend against routine complete endoscopic resection of the entire Barrett's segment compared with endoscopic resection of the visible lesion followed by ablation of the remaining Barrett's segment (strong recommendation, very low-quality evidence).
Summary of the Evidence: The patient-important outcomes for this clinical question were difference in progression rates to HGD/EAC, difference in rates of recurrence, and adverse events, specifically rates of stricture and bleeding (see evidence profile presented in Table 9 ). This recommendation was informed by a recent systematic review and meta-analysis by Desai et al 63 published in 2017. This meta-analysis included 774 patients from 9 studies of EMR of visible lesions followed by RFA of the remaining Barrett's segment (EMRþRFA) and 751 patients from 11 studies of describing complete EMR of the entire Barrett's segment (cEMR). One additional study of EMRþRFA was included in the analysis of adverse events (for a total of 863 patients). Because of the limited headto-head studies comparing these 2 strategies, the authors extracted data from prospective and retrospective cohort studies (including RCTs) and calculated pooled estimates of effect across studies for each of the efficacy and adverse events outcomes. The authors also conducted an indirect comparison of these 2 strategies using mixed logistic regression models. Across 9 studies of EMRþRFA (n Z 774), the pooled estimate for complete eradication of neoplasia (HGD/EAC) was 93.4% (95% CI, 90.8%-96.1%; I 2 Z 46%). Across 11 studies of cEMR, (n Z 747) the pooled estimate for complete eradication of neoplasia (HGD/EAC) was 94.9% (95% CI, 92.2%-97.5%; I 2 Z 72%) ( Supplementary  Fig. 3 , available online at www.giejournal.org). Although the following was not included in our evidence profile as a critical or important outcome, the authors also analyzed pooled estimates of rates of CE-IM. In the EMRþRFA group the pooled rate was 73.1% (95% CI, 63%-83.1%; I 2 Z 93.3%) and in the cEMR group, 79.6% (95% CI, 75.2%-84.1%; I 2 Z 52.48%) (Supplementary Fig. 3) .
Based on indirect comparisons of pooled estimates, no significant differences between these 2 strategies were detected for complete eradication of neoplasia or CE-IM. However, significant differences in rates of adverse events were noted. Based on indirect comparison, cEMR was more likely to cause strictures (OR, 4.73; 95% CI, 1.61-13.85; P Z .005), bleeding (OR, 6.88; 95% CI, 2.19-21.62; P Z .001), and perforations (OR, 7.00; 95% CI, 1.56-31.33; P Z .01) compared with EMRþRFA. There were no differences between the 2 groups with regards to recurrence rates of EAC (pooled estimate: EMRþRFA, 2 Z 51%]). Certainty in the Evidence: Across outcomes, the overall certainty was very low. There was concern about heterogeneity across the studies for both EMRþRFA and cEMR pooled effect estimates. Additionally, there were concerns about imprecision because of few events for the harm outcomes, and, finally, publication bias was suspected based on the Eggers regression test across the cEMR studies. An indirect comparison was performed comparing the pooled estimates for EMRþRFA and cEMR studies using mixed logistic regression, which added more uncertainty to the body of evidence comparing EMRþRFA with cEMR. Hence, the overall quality of evidence was very low.
Considerations: Despite the overall very low-quality evidence, the panel members made a strong recommendation against routine cEMR for BE patients with dysplasia. This recommendation placed a high value on avoiding adverse events. With relatively similar benefits regarding complete eradication of neoplasia and intestinal metaplasia, there were many more adverse events among patients undergoing cEMR compared with patients who underwent EMRþRFA, and thus the panel placed a high value on avoiding harms. There were limited data on cost/resource use and patient preferences to guide this clinical question.
Discussion: Given the lack of difference in outcomes (complete eradication and recurrence rates) between the 2 approaches and significantly higher adverse events associated with cEMR, the panel members agreed that performing EMR of all visible lesions followed by ablation of the remaining BE segment was the preferred strategy in patients undergoing EET. The main advantage of cEMR is the provision of true histology for the entire BE segment. The panel members acknowledge that the strategy of cEMR may be acceptable in a select group of patients. Whether there is a subgroup of BE-related neoplasia patients (multifocal disease, diffuse nodularity, select cases with short-segment BE) more likely to benefit from cEMR needs to be evaluated in future studies. Improvement in prevention of stricture formation post-cEMR is also required before this treatment strategy can be recommended as a primary treatment modality. Recommendation: In BE patients with dysplasia who have achieved CE-IM after EET, we suggest surveillance versus no surveillance (conditional recommendation, very low-quality evidence).
Summary of the Evidence: The primary outcomes for this clinical question were recurrence rates of intestinal metaplasia and neoplasia, progression rates to cancer, and EAC-specific and all-cause mortality between patients enrolled in surveillance programs after achieving CE-IM compared with those who are not. The outcome of recurrence of intestinal metaplasia and neoplasia was addressed using evidence from a recent systematic review and metaanalysis by Fujii-Lau et al. 51 This study aimed to determine the incidence of recurrent intestinal metaplasia and dysplasia after achieving CE-IM using treatment modalities that included RFA and EMR. From a total of 3311 identified studies, full texts from 144 studies were reviewed, and 39 studies (25 RFA, 13 stepwise complete EMR, 2 combined) were included in the final analysis. The pooled incidence rate of any recurrence was 7.5 (95% CI, 6.1-9.0) per 100 patient-years ( Supplementary Fig. 4 , available online at www.giejournal.org). The pooled incidence rate of intestinal metaplasia recurrence was 4.8 (95% CI, 3.8-5.9) per 100 patient-years and dysplasia recurrence rate was 2.0 (95% CI, 1.5-2.5) per 100 patient-years. Significant heterogeneity between studies was identified (I 2 Z 86) with no evidence of publication bias. A jackknife sensitivity analysis removing 1 study at a time did not meaningfully change the results. No data evaluated the impact of surveillance on progression rates to EAC, all-cause mortality, and EAC-related mortality after assessing the evidence.
Certainty in the Evidence: The quality of evidence was rated as very low, given the significant heterogeneity in studies reporting this outcome.
Considerations: The overall benefits and harms were important drivers for this recommendation. The potential adverse events of an active management strategy of routine endoscopic surveillance after achieving CE-IM include those associated with standard upper endoscopy with biopsy sampling and EET for management of recurrence of intestinal metaplasia and dysplasia (discussed above). The benefits include early detection of neoplasia and the potential to reduce the risk of progression to invasive EAC (although not demonstrated in any prospective trials). In addition, endoscopy is associated with added costs and creates a moderate burden to patients related to discomfort and time off work. The lack of surveillance and monitoring may contribute to patient anxiety. Limited data address the issue of patient values, preferences, and burden associated with either of these treatment approaches.
Discussion: Although the effectiveness of EET has been demonstrated, variable rates of recurrence of intestinal metaplasia and dysplasia have been reported after EET. A reliable estimate of the risk of recurrence after achieving 64 using Eggers regression test for the cEMR studies. zSignificant heterogeneity noted for the pooled estimate across the EMR þ RFA studies (I 2 Z 59.4%) and across the cEMR studies (I 2 Z 96.4%). xBecause of few events and failure to attain optimal information size, we rated down for imprecision across the EMR þ RFA and cEMR studies. {Significant heterogeneity noted for the pooled estimate across the cEMR studies (I 2 Z 69.4%).
CE-IM, as highlighted above, is critical in the education of physicians and patients before embarking on EET, determining cost-effectiveness of EET, and establishing surveillance guidelines (duration and frequency of surveillance endoscopy). 51, 52 Despite the lack of comparative data assessing the impact of surveillance endoscopy in patients achieving CE-IM, a recommendation of surveillance was provided given the risk of recurrence after achieving CE-IM. The panel members also agreed that patients in whom the goal of EET is to achieve complete eradication of dysplasia (select few patients) should also be enrolled in surveillance programs after achieving this endpoint.
Several issues remain unresolved even after a critical assessment of the evidence. Substantial heterogeneity noted in the recurrence rates could not be accounted for in the published analyses, and potential factors contributing to this heterogeneity include patient characteristics, variation in the baseline histology (proportion of patients with HGD/intramucosal EAC), EET treatment techniques and protocols, endoscopic surveillance intervals, surveillance biopsy protocols, confirmation of diagnosis by expert pathology review, differences in acid suppressive regimens, and variability in definition of recurrence. Recurrence of intestinal metaplasia or neoplasia is defined by the presence of intestinal metaplasia on surveillance biopsy specimens in the presence or absence of endoscopically visible BE after achieving CE-IM. 22 Although the number of endoscopies with negative biopsy specimens required to achieve CE-IM is not standardized (CE-IM defined by 1 or 2 consecutive negative endoscopies), no difference in recurrence rates have been reported based on the definition of CE-IM. 51, 53 Available data do not allow for a timeto-event analysis accounting for individual patient data and patients lost to follow-up. Although the temporality of recurrence after achieving CE-IM cannot be established with the available reports, recent reports suggest that most recurrences are reported within the first 3 years after achieving CE-IM. 53, 54 A limited number of studies report on the risk factors associated with recurrence (ongoing reflux and presence of erosive esophagitis, older age, nonwhite race, smoking, obesity, pretreatment BE length, number of EET sessions), and these associations need to be explored and confirmed in future studies. 51, 53, 54, [64] [65] [66] Surveillance intervals suggested by current guidelines are largely driven by expert opinion and low quality evidence. 2, 14 An initial endoscopic examination at 3 to 6 months after CE-IM is achieved is suggested followed by surveillance intervals based on pretreatment histology. For patients with baseline diagnosis of HGD, surveillance endoscopies every 3 months in the first year after CE-IM followed by endoscopies every 6 months in year 2 followed by yearly endoscopies has been suggested. For patients with LGD who have achieved CE-IM, the most recent American Gastroenterological Association guidelines suggest surveillance every year for 2 years and then every 3 years thereafter. 3 Consistent with recent guidelines and consensus documents, the panel agreed that histology is required for confirmation of recurrent intestinal metaplasia or neoplasia. 2, 14 The technique for surveillance biopsy sampling after achieving CE-IM has not been standardized. The biopsy protocol of obtaining biopsy specimens in 4 quadrants every 2 cm throughout the length of original BE segment and any visible columnar mucosa/lesion has been suggested. 3 The panel members reviewed recent data suggesting the lack of additional yield from biopsy specimens obtained >2 cm from the gastroesophageal junction in the absence of any visible lesion in the neosquamous epithelium. 67 The importance of medical antireflux therapy, with a goal of minimizing the frequency of reflux symptoms, achieving the absence of esophagitis on endoscopy, and potentially reducing the risk of recurrence, is critical in the management of patients after achieving CE-IM. 2, 14, 54 A recent observational study demonstrated that EET with a structured reflux management protocol achieved a high rate of CE-IM with a significantly lower rate of recurrence after EET (recurrence of IM, 4.8%; dysplasia, 1.5%) compared with published literature. 54 
FUTURE DIRECTIONS
Systematic review of the literature related to EET in BE patients identified several knowledge gaps. Given the significant interobserver variability among pathologists, there is a need for international standardization and validation of histologic criteria (especially for LGD), creation of a uniform reporting system, and training among pathologists. 3 Limited data exist on the extent of training required to perform EET, and a formal determination of what constitutes "competency" in EET by using a validated competency assessment tool is required.
14,68-70 Experts suggest that EET practitioners need to (1) demonstrate expertise in the use of high-definition white-light endoscopy and optical chromoendoscopy in the inspection of BE, (2) and (4) be able to manage adverse events related to EET (including recurrences). 14 Another area of interest for future research is the identification and application of risk factors for disease progression in BE patients. Risk stratification and development of reliable and objective predictive models to identify those NDBE and LGD patients most likely to progress and benefit from EET is critical. Such models should include a combination of demographic variables, endoscopic findings, histopathologic assessment, and biomarkers. 3 Furthermore, future prospective studies that use standardized definitions for study endpoints and focus on durability of EET and recurrence risk as the primary outcomes are required to more precisely define the annual recurrence risk and the predictors associated with recurrence. This will allow for evidence-based recommendations with regard to surveillance endoscopic and biopsy protocols after successful EET of BE-related neoplasia patients with the goal of stopping or reducing the frequency of surveillance in low-risk individuals and enrolling high-risk patients in an intensive surveillance protocol. 51 The role of gastroesophageal reflux monitoring and pH control in patients undergoing surveillance and EET with a focus on reducing progression rates or achieving CE-IM and reducing rates of recurrence, respectively, needs to be addressed in future studies. Finally, although GI societal endorsed quality indicators in EET have been published, 14, 41, 61 these will need to be refined and updated based on developments in this field. Future studies will need to assess the challenges in the process of implementation of these quality indicators and most importantly evaluate the impact of implementation of these quality indicators on key patient outcomes (progression to cancer, adverse events, and mortality).
SUMMARY AND CONCLUSIONS
These evidence-based ASGE practice guidelines for EET in BE patients were developed using the GRADE methodology. 24 In addition, these guidelines comply with the standards for guideline development set forth by the Institute of Medicine for the creation of trustworthy guidelines. This guideline evaluated the available data for EET in BE patients within the context of several key clinical scenarios encountered in clinical practice, such as the role of an expert pathology review; optimal management strategy of BE patients with LGD, HGD, and intramucosal EAC; the role of EMR; the optimal strategy for EET; and management of patients after achieving CE-IM. This guideline, along with a clinical decision tool (Fig. 9) , aims to help clinicians understand the published literature and the quality of available data with the ultimate goal of optimizing care of these patients.
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